The Biodesix leadership team brings together expertise in management, molecular diagnostics, advanced analysis of complex data sets, and commercial operations.
|Chief Executive Officer and Director|
|Chief Technology Officer
|Chief Medical Officer
|Chief Financial Officer|
|Vice President, Clinical Development & Medical Affairs|
|Vice President, Business Development & Strategic Marketing|
|Vice President, Legal & Regulatory Affairs|
|Vice President, Human Resources & Operational Effectiveness
Chief Executive Officer and Director
Mr. Brunel has been involved in enterprise software for over 25 years and has been involved in molecular diagnostics since 2000. Mr. Brunel was a founder and CEO of Unidata, Inc. when it merged with Vmark Software to create Ardent Software, Inc., where he was President and COO. He was also a member of the Board of Ardent until it was sold to Informix in 1999. Mr. Brunel was also a co-founder and President of SomaLogic, Inc., a company focused on creating protein capture arrays for sensitive, high-throughput, quantitative diagnostics. Mr. Brunel is also on the board of Anark Corporation and Xyleme, Inc.
Chief Technology Officer
Dr. Röder is a company founder and author or co-author of more than 100 publications/talks in theoretical physics and computational sciences. Dr. Röder obtained his D.Phil at Oxford University, and went on to become an eminent theoretical physicist with positions at University of Hanover and Bayreuth (Germany) and Los Alamos National Laboratory. He has led projects involving the diagonalization of gigadimensional matrices, has done pioneering work in the microscopic mechanisms of colossal magneto resistive perovskites, and initiated the first use of large-scale inverse problem techniques in the analysis of neutron scattering data. Recruited from Los Alamos, Dr. Röder serves as Biodesix’ CTO, leading the Research and Development side of the Company and designing functionality for next generation products and services. Dr. Röder is a Rhodes Scholar.
Chief Medical Officer
Rick is the former Chief Medical Officer of CombiMatrix, where he focused on applied genomic and molecular diagnostics in the CombiMatrix CLIA laboratory. Prior to CombiMatrix, Rick was the Chief Medical Officer for Affymetrix, where he led applied genomics, new technology development, and regulatory affairs. Rick has 30 years of experience in applying biomarkers to clinical medicine, and is recognized as a leader in Personalized Medicine. As a Board Certified Clinical Pathologist, Dr. Hockett’s specialties include molecular diagnostics, clinical application of technology, and biomarker strategies. Rick started his career in industry as a Medical Fellow II, Group Leader for Genomic Medicine at Eli Lilly and Company, where he developed the pharmacogenomic program and oversaw the application of genetic biomarkers to clinical drug development. He was also instrumental in developing the DMET analysis system, which has become the most comprehensive technology for the measurement of DNA variation in metabolism of pharmaceuticals. Dr. Hockett started his career as an academic pathologist in the Department of Pathology at the University of Alabama, Birmingham, where he oversaw the Clinical Immunology and Molecular Diagnostic laboratories and his research focused on developmental immunology and HIV disease. Rick received his M.D. degree from the University of Minnesota, and pursued a residency in Clinical Pathology at Washington University, St. Louis.
Chief Financial Officer
Mr. Ronchetti is an entrepreneur and finance professional with 20 years of domestic and international experience. Most recently, he was Chief Financial Officer of NetRegulus, a regulatory compliance software company that was sold to Parametric Technology Corporation (Nasdaq: PMTC). Prior to that, he was a Director in the London office of General Electric’s venture capital arm, GE Equity. He also founded a corporate finance boutique in the Czech Republic, ran Central European acquisition finance for Erste Bank, the region’s leading financial institution, and negotiated corporate sponsorship agreements on behalf of the International Olympic Committee. Mr. Ronchetti has a BA in Economics from Stanford University, and an MBA from the Anderson School at UCLA.
Vice President of Clinical Development and Medical Affairs
Dr. Spinella brings to Biodesix over 20 years of experience in drug development and the discipline of translational medicine. Most recently, Dom was Executive Director and Head of Translational and Molecular Medicine for the Pfizer Biotherapeutics Division. He also headed Translational Medicine for Pfizer Oncology and led the clinical and translational biomarker work for the company’s oncology portfolio. Prior to this, he spent eight years at Chugai Pharmaceuticals USA in positions of increasing responsibility, most recently as Vice President of Exploratory Research. Dr. Spinella has served on several national and international cancer biomarker development bodies and is an author or co-author of more than 50 peer-reviewed articles and abstracts. He received his Bachelor of Science degree in Biology from Syracuse University, and his Master of Science and Ph.D. degrees in genetics and immunology respectively from Rutgers University.
Vice President of Business Development and Strategic Marketing
Dr. Beresford is Vice President of Business Development and Strategic Marketing. His expertise includes leading groups that provide products and services to oncology-focused pharmaceutical and biotechnology companies for identifying and commercializing companion diagnostics. Prior to joining Biodesix, Dr. Beresford held a number of senior management positions at Ventana Medical Systems and Roche Diagnostics (after the acquisition of Ventana by Roche in early 2008) including Vice President, General Manager of Translational Diagnostics. He received a Ph.D. in Immunology from the Sackler School of Graduate Biomedical Sciences at Tufts University School of Medicine and was an Instructor and Junior Investigator at the Center for Blood Research at Harvard Medical School.
Vice President of Legal and Regulatory Affairs
Mr. Bojar joins Biodesix from Snell & Wilmer L.L.P., a prestigious regional law firm headquartered in Phoenix, Arizona, where he developed the Denver office’s business and finance and biotechnology practice groups. Mr. Bojar’s practice focused on technology transfer, licensing, corporate, securities, and commercial transactions, including finance, venture capital, private equity and all aspects of representing emerging growth companies. As a member of the United States Patent Bar, Mr. Bojar also concentrated in the areas of intellectual property. Mr. Bojar received a J.D. from Marquette University Law School and a M.S. in biomedical sciences from the Medical College of Wisconsin. Mr. Bojar is responsible for the Company’s (i) quality and medical affairs compliance and regulatory strategy, (ii) technology transfer and collaboration development, (iii) intellectual property portfolio management, and (iv) and other general corporate matters.
Vice President of Human Resources and Operational Effectiveness
Jim Purvis is a seasoned operating, human resources and organizational development professional with over 30 of organizational development experience. He joins Biodesix from Align Organizational Performance Engineering, a consulting company that provides CEO coaching, outsourced HR executive and strategic leadership, and uses proprietary tools to measure and improve organizational performance directly linked to operational and financial metrics. In addition to being Managing Partner of Align, Jim has done extensive work in the areas of business strategy development, executive coaching, major change management, organizational performance improvement and team development. His corporate experience includes AIMCO (Apartment Investment and Management Company) ; SomaLogic, (a privately funded biotechnology company); ALCOA; Eastern Airlines/Texas Air; Starwood /Westin Hotels and Resorts, and TCI/ATT Broadband (Tele-Communications, Inc.) .